Latest Articles
Rising Cancer Rates Among Young Adults Spur Global Alarm - Evrim Ağacı
Rising Cancer Rates Among Young Adults Spur Global Alarm Evrim Ağacı
Published: Oct. 23, 2025, 2:54 a.m.
Frontline Strategy: Why You Must Use IO Upfront in Endometrial Cancer - Targeted Oncology
Frontline Strategy: Why You Must Use IO Upfront in Endometrial Cancer Targeted Oncology
Published: Oct. 22, 2025, 6:21 p.m.
Hysteroscopic diagnostic criteria highly accurate and sensitive for detecting chronic endometritis: Study - Medical Dialogues
Hysteroscopic diagnostic criteria highly accurate and sensitive for detecting chronic endometritis: Study Medical Dialogues
Published: Oct. 22, 2025, 4 p.m.
Mayo TD says endometriosis framework is more aspirational than actionable - Connaught Telegraph
Mayo TD says endometriosis framework is more aspirational than actionable Connaught Telegraph
Published: Oct. 22, 2025, 3:39 p.m.
Embryo-maternal cross-talk: key players in successful implantation and live birth rates - Reproductive Biology and Endocrinology
Embryo-maternal cross-talk: key players in successful implantation and live birth rates Reproductive Biology and Endocrinology
Published: Oct. 22, 2025, 11:49 a.m.
Why NFX Invested in Cyclana Bio: A Bioplatform Building Physiologically Accurate Human Tissue Models - NFX
Why NFX Invested in Cyclana Bio: A Bioplatform Building Physiologically Accurate Human Tissue Models NFX
Published: Oct. 21, 2025, 4:16 p.m.
Macrophages in endometriosis: key roles and emerging therapeutic opportunities—a narrative review - Reproductive Biology and Endocrinology
Macrophages in endometriosis: key roles and emerging therapeutic opportunities—a narrative review Reproductive Biology and Endocrinology
Published: Oct. 21, 2025, 11:24 a.m.
Integrative transcriptomic analysis identifies shared EndMT-related gene signatures in endometriosis and recurrent miscarriage - Nature
Integrative transcriptomic analysis identifies shared EndMT-related gene signatures in endometriosis and recurrent miscarriage Nature
Published: Oct. 21, 2025, 9:39 a.m.
Faeth Therapeutics' $92 Million Total Funding Powers PIKTOR Phase 2 Following 80% Response Rate in Endometrial Cancer - BioSpace
Faeth Therapeutics' $92 Million Total Funding Powers PIKTOR Phase 2 Following 80% Response Rate in Endometrial Cancer BioSpace
Published: Oct. 21, 2025, 5:15 a.m.
Endometriosis rates double in 10 years, new research reveals - bodyandsoul.com.au
Endometriosis rates double in 10 years, new research reveals bodyandsoul.com.au
Published: Oct. 21, 2025, 1:04 a.m.
Link copied to clipboard!